Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.79 |
| ▸ | EGFR | P00533 | 13/20 | 0.79 |
| ▸ | NQO2 | P16083 | 1/20 | 0.79 |
| ▸ | FECH | P22830 | 1/20 | 0.79 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.79 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21272284 | 0.90 | EGFR (0.65) | ERBB2EGFRNQO2FECHMYH14 | |
| Tucatinib SCHEMBL29653672 | 0.88 | ERBB2 (1.00) | ERBB2EGFRNQO2FECHMYH14 | |
| Tucatinib SCHEMBL29351516 | 0.88 | ERBB2 (1.00) | ERBB2EGFRNQO2FECHMYH14 | |
| Tucatinib SCHEMBL1193050 | 0.88 | ERBB2 (1.00) | ERBB2EGFRNQO2FECHMYH14 | |
| Tucatinib SCHEMBL29351934 | 0.88 | ERBB2 (1.00) | ERBB2EGFRNQO2FECHMYH14 | |
| Tucatinib SCHEMBL29475609 | 0.88 | ERBB2 (1.00) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL20629890 | 0.87 | ERBB2 (0.66) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL20629639 | 0.87 | EGFR (0.64) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL20629435 | 0.87 | EGFR (0.64) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL20629889 | 0.84 | ERBB2 (0.74) | ERBB2EGFRNQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | Shanghai Pharmaceuticals Holding Cd., Ltd. (CN) | 2023-02-14 | — | — | US | disclosed |
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| EP-3677583-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2020-07-08 | — | — | EP | disclosed |
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2019-03-28 | — | — | US | disclosed |
| WO-2019042409-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | 上海医药集团股份有限公司 | 2019-03-07 | — | — | WO | disclosed |
| EP-3424928-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-10143692-B2 | Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them | ARRAY BIOPHARMA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180140603-A1 | POLYMORPHS OF ARRY-380, A SELECTIVE HER2 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ARRAY BIOPHARMA INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | ERBB2, EGFR, ERBB4 | ERBB2 1/4885EGFR 2/4885NQO2 1434/4885 |
| US-10143692-B2 | Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them | ERBB2, ERBB3, ERBB4 | ERBB2 1/4885EGFR 5/4885NQO2 662/4885 |
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | ERBB2, EGFR, ERBB4 | ERBB2 1/4885EGFR 2/4885NQO2 1483/4885 |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | ERBB2, EGFR, ERBB4 | ERBB2 1/4885EGFR 2/4885NQO2 1250/4885 |
| US-20180140603-A1 | POLYMORPHS OF ARRY-380, A SELECTIVE HER2 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ERBB2, ERBB3, ERBB4 | ERBB2 1/4885EGFR 5/4885NQO2 662/4885 |
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | ERBB2, EGFR, ERBB4 | ERBB2 1/4885EGFR 2/4885NQO2 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.